Research programme: CNS disorders gene therapies - SalioGen Therapeutics
Latest Information Update: 06 Sep 2024
At a glance
- Originator SalioGen Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 01 Aug 2024 Early research in CNS disorders in USA (Parenteral) prior to August 2024 (SalioGen Therapeutics pipeline, August 2024)